Abbisko Cayman Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Abbisko Cayman non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

2.8%

Rendimento del riacquisto

Rendimento totale per gli azionisti	2.8%
Rendimento futuro dei dividendi	0%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

Sep 30

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Jan 09

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Nov 01

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Jun 08

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di 2256 siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di 2256 siano aumentati.

Rendimento dei dividendi rispetto al mercato

Abbisko Cayman Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di 2256 rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (2256)	n/a
Fondo del 25% del mercato (HK)	3.3%
Top 25% del mercato (HK)	8.1%
Media del settore (Biotechs)	1.1%
Analista previsionale (2256) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di 2256 rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di 2256 rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di 2256 per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché 2256 non ha segnalato alcun pagamento.

Abbisko Cayman Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Abbisko Cayman Limited (SEHK:2256) commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.

Recent updates

Consensus EPS estimates fall by 45%

Abbisko Cayman Limited Announces Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

First half 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.32 loss in 1H 2023)

Abbisko Cayman Limited to Report First Half, 2024 Results on Aug 12, 2024

Abbisko Therapeutics Co., Ltd. Presents New Phase II Clinical Data of Its Highly Selective FGFR4 Inhibitor Irpagratinib (ABSK011) in Combination with Atezolizumab for the 2024 Esmo-Gi Congress

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary

Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

Founder recently bought HK$358k worth of stock

Consensus revenue estimates decrease by 37%

Consensus EPS estimates fall by 89%

Abbisko Cayman Limited (SEHK:2256) commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.

Abbisko Cayman Limited, Annual General Meeting, Jun 18, 2024

Abbisko Cayman Limited to Report Fiscal Year 2023 Results on Mar 12, 2024

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib (ABSK021)

Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib (ABSK021) in China

Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051

Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Founder recently bought HK$257k worth of stock

Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology

Abbisko Cayman Limited Announces Absk011 Hcc Combo Clinical Trial Approved by Nmpa

Founder recently bought HK$121k worth of stock

Consensus revenue estimates increase by 2,172%

Abbisko Cayman Limited to Report First Half, 2023 Results on Aug 15, 2023

Abbisko Cayman Limited Announces Resignation of Dr. XIA Gavin Guoyao as Non-Executive Director

Abbisko Therapeutics Co., Ltd. to Present the Updated Clinical Phase Ib Data of Pimicotinib (ABSK021)

US FDA Grants Breakthrough Therapy Designation for CSF-1R Inhibitor Pimicotinib(ABSK021) of Abbisko Therapeutics

Less than half of directors are independent

Abbisko Therapeutics Co., Ltd. Completed the Dosing of the First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Abbisko Cayman Limited Appoints Zhang Zidong as Chief Financial Officer

Less than half of directors are independent

Consensus forecasts updated

Key Executive recently bought HK$1.1m worth of stock

Less than half of directors are independent

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti